An interesting finding in this work is that in CD34+ cells from patients at blastic phase, treatment with IM/BOR and IM/PSI significantly inhibits BFU-E but not CFU-GM (Figure 3A, lower panel), suggesting that cells from CML at blastic phase represent a heterozygous population which might respond diversely to drug treatment, and erythroleukemia cells seem to be more sensitive to IM/BOR combination. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.